Psychedelics

Clinical Trial Explores Psychedelic Treatment for Depression

LOS ANGELES- In a move within the field of psychiatric treatment, MindBio Therapeutics Corp. has announced the launch of its Phase 2B clinical trial, investigating the potential of psychedelics...

Indiana’s Pioneering Psilocybin Research Bill Awaits Governor’s Approval

LOS ANGELES- In a groundbreaking legislative move, Indiana stands on the precipice of advancing psilocybin research, following the...

Cybin Eyes $150 Million Boost Through Private Placement to Propel Psychedelic Drug Development

Cybin Inc., a firm at the forefront of psychedelic drug development, announced its plan on Wednesday to secure...

atai Life Sciences Advances VLS-01, A Novel DMT-Based Treatment

LOS ANGELES- atai Life Sciences a biotechnology company specializing in mental health treatments, is making strides in the...

FDA’s ‘Breakthrough’ Nod to MM120, An LSD-Derivative, for Anxiety Relief

LOS ANGELES- In a significant development within the field of psychedelic therapy, the Food and Drug Administration (FDA)...
spot_img

Clinical Trial Explores Psychedelic Treatment for Depression

LOS ANGELES- In a move within the field of psychiatric treatment, MindBio Therapeutics Corp. has announced the launch of its Phase 2B clinical trial,...

Indiana’s Pioneering Psilocybin Research Bill Awaits Governor’s Approval

LOS ANGELES- In a groundbreaking legislative move, Indiana stands on the precipice of advancing psilocybin research, following the final approval of a bill aimed...

Cybin Eyes $150 Million Boost Through Private Placement to Propel Psychedelic Drug Development

Cybin Inc., a firm at the forefront of psychedelic drug development, announced its plan on Wednesday to secure approximately $150 million in funding through...

atai Life Sciences Advances VLS-01, A Novel DMT-Based Treatment

LOS ANGELES- atai Life Sciences a biotechnology company specializing in mental health treatments, is making strides in the development of a groundbreaking approach to...

FDA’s ‘Breakthrough’ Nod to MM120, An LSD-Derivative, for Anxiety Relief

LOS ANGELES- In a significant development within the field of psychedelic therapy, the Food and Drug Administration (FDA) has recognized the LSD-analog substance MM120,...

New Mexico Advances Psilocybin Research with Memorial Legislation

-LOS ANGELES- In a significant move toward exploring alternative therapeutic treatments, New Mexico Governor Michelle Lujan Grisham has signed Senate Memorial 12 (SM-12), initiating...
spot_img